Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07110233 · ClinicalTrials.gov registry record · NA
Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma
A NA study, sponsored by University of California, San Francisco.
- Not yet
- Registry status
- NA
- Development phase
- 64
- Enrollment target
NCT07110233 is a NA study that has not yet begun recruiting, run by University of California, San Francisco. The registered enrollment target is 64 participants.
The verdict
NCT07110233, a NA study, has not yet begun recruiting, sponsored by University of California, San Francisco.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
Study Summary
This is a prospective, single-blinded, single-arm, open-label Phase II trial of trans-arterial radiation segmentectomy using Yttrium-90 glass microspheres (TheraSphere®) for Hepatocellular Carcinoma (HCC) participants with unresectable Barcelona clinic liver cancer (BCLC) stage A disease.
Interventions
- DEVICE TheraSphere® Yttrium-90 microspheres
- OTHER Health Related Quality of Life Questionnaires (HRQOL)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2026-10-01 |
| Est. Completion | 2029-03-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07110233
The ClinicalTrials.gov registry entry for NCT07110233 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TheraSphere® Yttrium-90 microspheres is the first listed.
NCT07110233 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07110233 about?
NCT07110233 is a clinical study titled "Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma". This is a prospective, single-blinded, single-arm, open-label Phase II trial of trans-arterial radiation segmentectomy using Yttrium-90 glass microspheres (TheraSphere®) for Hepatocellular Carcinoma (HCC) participants with unresectable Barcelona clinic liver cancer (BCLC) stage A disease.
What is the current status of trial NCT07110233?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 64 participants. The study started on 2026-10-01. Estimated completion is 2029-03-31.
What interventions are being tested in trial NCT07110233?
The interventions under investigation include: TheraSphere® Yttrium-90 microspheres (DEVICE), Health Related Quality of Life Questionnaires (HRQOL) (OTHER).
Who is sponsoring clinical trial NCT07110233?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.